|
|
|
| Analysis of Quality of Life and Neutrotransmitter Tested by Encephalofluctuograph of Venlafaxine in the Treatment of Depression |
| LIU Tao, et al |
| Chongqing Mental Health Center, Chongqing 400000, China |
|
|
|
|
Abstract Objective: Research the clinical efficacy , serological indexes and neutrotransmitter of Venlafaxine in the treatment of depression . Methods: Select 168 depression patients between October 2015 and January 2017 of our hospital , divided them into two groups called control group and research group randomly, the control group was taken fluoxetine , while research group was combined with Venlafaxine , compared the SF-36 score , HAMD score , serological indexes and neutrotransmitter factors of two groups before and after treatment .Results:The SF-36 score of two groups before treatment had no statistical difference(P>0.05),the SF-36 score of research group 4 weeks and 8 weeks after treatment were both much higher than control group , and had statistical difference(P<0.05),the SF-36 score of two groups 4 weeks and 8 weeks after treatment all had statistical difference with pre-treatment respectively(P<0.05).The HAMD score of two groups had no statistical difference(P>0.05),the HAMD score of research group 4 weeks and 8 weeks after treatment were both much higher than control group , and had statistical difference(P<0.05),the HAMD score of two groups 4 weeks and 8 weeks after treatment all had statistical difference with pre-treatment respectively(P<0.05).The serological indexes of two groups such as TNF-α、IL-1β、IL-6 had no statistical difference(P>0.05),the TNF-α、IL-1β、IL-6 of research group 4 weeks and 8 weeks after treatment were both much lower than control group , and had statistical difference(P<0.05),the TNF-α、IL-1β、IL-6 level of two groups 4 weeks and 8 weeks after treatment all had statistical difference with pre-treatment respectively(P<0.05).The neutrotransmitter indexes such as Glu、NE、Ach、DA、5-HT and GABA of two groups before treatment had no statistical difference(P>0.05),Glu level of research group 4 weeks and 8 weeks after treatment were both much lower than control group , NE、Ach、DA、5-HT and GABA levels of research group of 4 weeks and 8 weeks after treatment were all much higher than control group , and had statistical difference(P<0.05),Glu、NE、Ach、DA、5-HT and GABA levels of two groups of 4 weeks and 8 weeks after treatment had statistical difference with pre-treatment respectively(P<0.05).Conclusion:The function mechanism of Venlafaxine is related to the expression of cytokines and the regulation of neutrotransmitters ,and the effect is accurate , which can significantly improve the quality of life of patients and promote the alleviation of depression symptoms , and is worthy of clinical promotion.
|
|
|
|
|
|
[1]Schwartz TL,Santarsieri D.Neutral implications of psychotherapy,pharmacotherapy,and combined treatment in major depressive disorder[J].Mens Sana Monogr,2016,14(1):30~45.
[2] Sachs-ericsson N,Hames JL,JOINER TE,et al.Differences between suicide attempters and nonattempters in depressed older patients:depression severity,white-matter lesions,and cognitive functioning[J].Am Geriatr Psychiatry,2014,22(1):75~85.
[3] Harrisberger F,Spalek K,Smieskova R,et al.The association of the BDNF Val66Met polymorphism and the hippocampal volumes in healthy humans:a joint meta-analysis of published and new data[J].Neurosci Biobehav Rev,2014,42(5):267~278.
[4] Ali A,Yesudas K F,Palayat A M,et al.Depression and menopaused symptoms in perimenopausal women attending primary care[J].J Evi Based Med Health,2017,4(44):2677~2681.
[5] 杨和增,单菲,李敏智.围绝经期抑郁症患者文拉法辛治疗前后脑源性神经营养因子的变化[J].实用医学杂志,2018,34(3):457~459.
[6] Guuzel O P,Boysan M,Smolensky M H,et al.Comparison of venlafaxin alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder[J].Journal of Clinical Psychiatry,2015,76(5):645.
[7] Cheon E J,Lee K H,Park Y W,et al.Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors:a randomized,prospective,open-label study[J].Journal of Clinical Psychopharmacology,2017,37(3):113~115. |
|
|
|
2019, Vol. 25 
